New hope for Drug-Resistant breast cancer: phase 3 trial launches

NCT ID NCT07354022

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a new drug called HRS-8080, combined with dalpiciclib, works better than the standard treatment (fulvestrant plus dalpiciclib) for people with advanced breast cancer that has become resistant to hormone therapy. About 912 women aged 18-75 with locally advanced or metastatic breast cancer will take part. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-8080 tablet combined with dalpiciclib
What this could lead to: If it works, this could offer a new treatment option for advanced breast cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a large phase 3 trial, but it's still experimental. The new drug may not improve outcomes or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Contacts and locations

Locations

Chinese PLA General Hospital Fifth Medical Center
RECRUITING

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.